



U.S. National Library of Medicine  
National Center for Biotechnology Information

**NLM Citation:** Hershberger RE, Jordan E. *LMNA*-Related Dilated Cardiomyopathy. 2008 Jun 12 [Updated 2022 Mar 17]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.  
**Bookshelf URL:** <https://www.ncbi.nlm.nih.gov/books/>



## LMNA-Related Dilated Cardiomyopathy

Ray E Hershberger, MD<sup>1</sup> and Elizabeth Jordan, MMSc, CGC<sup>2</sup>

Created: June 12, 2008; Updated: March 17, 2022.

### Summary

### Clinical characteristics

*LMNA*-related dilated cardiomyopathy (DCM) is characterized by left ventricular enlargement and/or reduced systolic function preceded (sometimes by many years) by or accompanied by conduction system disease and/or arrhythmias. *LMNA*-related DCM usually presents in early to mid-adulthood with symptomatic conduction system disease or arrhythmias, or with symptomatic DCM including heart failure or embolus from a left ventricular mural thrombus. Sudden cardiac death can occur, and in some instances is the presenting manifestation; sudden cardiac death may occur with minimal or no systolic dysfunction.

### Diagnosis/testing

The diagnosis of *LMNA*-related DCM is established in a proband with suggestive findings and a heterozygous pathogenic variant in *LMNA* identified by molecular genetic testing.

### Management

*Treatment of manifestations:* Chronic atrial fibrillation is treated initially with attempts to restore normal sinus rhythm, anticoagulation, and rate control. Symptomatic supraventricular arrhythmias are usually treated with pharmacologic therapy or ablation; symptomatic bradyarrhythmias or significant heart block is treated with an electronic pacemaker. Symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, and resuscitated sudden cardiac death are treated with an implantable cardioverter defibrillator (ICD) and drug therapy as needed. Because risk for sudden cardiac death in *LMNA*-related DCM accompanies heart block and bradyarrhythmias, ICD use (rather than just pacemaker use) has been recommended for all indications. Treatment of symptomatic DCM, including heart failure, is pharmacologic with ACE inhibitors, beta blockers, and other conventional approaches. Progressive deterioration in left ventricular function is treated with an ICD. Cardiac transplantation or other advanced therapies may be considered for refractory disease in persons receiving comprehensive care from cardiovascular disease experts.

**Author Affiliations:** 1 Professor of Medicine, Divisions of Human Genetics and Cardiovascular Medicine The Ohio State University Columbus, Ohio; Email: [ray.hershberger@osumc.edu](mailto:ray.hershberger@osumc.edu). 2 Assistant Professor, Division of Human Genetics The Ohio State University Columbus, Ohio; Email: [elizabeth.jordan@osumc.edu](mailto:elizabeth.jordan@osumc.edu).

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

*Surveillance:* Individuals with an *LMNA* pathogenic variant who are found to have any EKG abnormality should undergo a cardiovascular evaluation for disease progression (EKG, 24-48 hour rhythm monitoring, LV function measurement) at least annually. Asymptomatic individuals with a pathogenic *LMNA* variant should undergo cardiovascular evaluation (medical history, physical examination, echocardiogram, and EKG) every one to two years and/or whenever new symptoms arise. In families with a known *LMNA* pathogenic variant, at-risk individuals for whom genetic testing is not possible should have yearly cardiovascular evaluation. At onset of new symptoms an immediate evaluation for evidence of DCM and/or conduction system disease is indicated regardless of genetic status.

*Evaluation of relatives at risk:* To facilitate prompt diagnosis, targeted *LMNA* genetic testing when the family-specific pathogenic variant is known; otherwise regular surveillance with cardiovascular screening tests.

*Pregnancy management:* Pregnancy is contraindicated in women with DCM. Pregnant women with DCM should be followed by a high-risk obstetrician. At-risk women with unknown genetic status should undergo a cardiovascular evaluation and be offered genetic counseling, ideally prior to pregnancy.

## Genetic counseling

*LMNA*-related DCM is inherited in an autosomal dominant manner. Some individuals diagnosed with *LMNA*-related DCM have an affected parent; the proportion of individuals with *LMNA*-related DCM caused by a *de novo* pathogenic variant is unknown. Each child of an individual with *LMNA*-related DCM has a 50% chance of inheriting the pathogenic variant. Once an *LMNA* pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic testing are possible.

## Diagnosis

### Suggestive Findings

*LMNA*-related dilated cardiomyopathy (DCM) **should be considered** in individuals with the following clinical findings and family history.

#### Clinical findings

- **A clinical diagnosis of idiopathic DCM** (etiology not attributed to coronary artery disease, structural heart disease, or other established clinical conditions that may cause DCM; see [Dilated Cardiomyopathy Overview](#)), almost always in the setting of conduction system disease and/or supraventricular or ventricular arrhythmias. The diagnosis of DCM is based on the principal findings of left ventricular enlargement and/or reduced systolic function (other causes excluded):
  - **Left ventricular enlargement** is most commonly identified with two-dimensional echocardiography, optimally assessed by a height- and sex-based approach [Vasan et al 1997], or by cardiac magnetic resonance (CMR) imaging.
  - **Reduced systolic function** is described clinically as a reduction in left ventricular ejection fraction, which can be measured by two-dimensional echocardiography, angiography, radioisotope scanning, or MRI of left ventricular function. An ejection fraction of less than 50% is considered systolic dysfunction [Bozkurt et al 2021].
- **The key distinguishing characteristic of *LMNA*-related DCM** is that conduction system disease and/or arrhythmias almost always occur prior to or in association with the evolution of DCM and commonly before the development of heart failure (see Clinical Description).

**Family history** is consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations). A detailed three- to four-generation family history looking for heart failure, DCM, cardiac transplantation, pacemakers or implantable cardiac defibrillators, unexplained sudden death, unexplained

cardiac conduction system disease and/or arrhythmia, or unexplained stroke or other thromboembolic disease in relatives is indicated to assess the possibility of *LMNA*-related DCM. Conduction system disease, particularly with pacemakers, is particularly suggestive of *LMNA*-related DCM.

## Establishing the Diagnosis

The diagnosis of *LMNA*-related DCM is **established** in a proband with suggestive findings and a heterozygous pathogenic variant in *LMNA* identified on molecular genetic testing (see Table 1).

Note: Identification of a heterozygous *LMNA* variant of uncertain significance does not establish or rule out the diagnosis of this disorder.

Because the phenotype of *LMNA*-related DCM is indistinguishable from many other inherited disorders with DCM and DCM with a highly arrhythmic presentation, recommended molecular genetic testing approaches include use of a **multigene panel** or **comprehensive genomic testing**.

Note: Single-gene testing (sequence analysis of *LMNA*, followed by gene-targeted deletion/duplication analysis) for suspected *LMNA*-related DCM is rarely useful and typically NOT recommended.

- **A comprehensive cardiomyopathy multigene panel** that includes *LMNA* and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. When prominent arrhythmia with minimal DCM phenotype is present, a **combined cardiomyopathy and arrhythmia multigene panel** should be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

- **Comprehensive genomic testing** does not require the clinician to determine which gene is likely involved. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

**Table 1.** Molecular Genetic Testing Used in *LMNA*-Related Dilated Cardiomyopathy

Gene <sup>1</sup>	Method	Proportion of Probands with a Pathogenic Variant <sup>2</sup> Detectable by Method
<i>LMNA</i>	Sequence analysis <sup>3</sup>	>99% <sup>4</sup>
	Gene-targeted deletion/duplication analysis <sup>5</sup>	<1% <sup>4, 6</sup>

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

6. At least three reports have identified *LMNA*-related DCM resulting from deletions [van Tintelen et al 2007, Gupta et al 2010, Cirino et al 2020].

## Clinical Characteristics

### Clinical Description

*LMNA*-related dilated cardiomyopathy (DCM) is characterized by left ventricular enlargement and/or reduced systolic function frequently preceded or accompanied by significant conduction system disease.

**Age of onset.** While *LMNA*-related DCM usually presents in adulthood either with conduction system disease commonly accompanied by arrhythmias or with symptomatic DCM (including heart failure or embolus from a left ventricular mural thrombus), it may also be present in asymptomatic individuals: conduction system disease, arrhythmia, or DCM may be discovered during a medical evaluation conducted for another reason (e.g., a routine preoperative EKG) or clinical screening of at-risk relatives [Kumar et al 2016].

**Presenting signs, timing, and progression.** Family studies suggest that conduction system disease commonly precedes the development of DCM by a few years to a decade or more. In a study involving 64 individuals with an *LMNA* pathogenic variant, the median time differential from EKG abnormalities to observed left ventricular dysfunction was seven years [Brodt et al 2013]. In another retrospective study of 122 individuals with *LMNA* pathogenic variants, of those who had preserved left ventricular function and no heart failure at the time of presentation, new-onset left ventricular dysfunction or heart failure was observed in ~24% and 7% of individuals, respectively, after seven years [Kumar et al 2016].

- **Conduction system involvement** usually starts with disease of the sinus node and/or atrioventricular node that can manifest as sinus bradycardia, sinus node arrest with junctional rhythms, or heart block (commonly first-degree heart block that progresses to second- and third-degree block). The following are also common:
  - Symptomatic bradyarrhythmias requiring cardiac pacemakers
  - Supraventricular arrhythmias including atrial flutter, atrial fibrillation, supraventricular tachycardia, and the sick sinus syndrome (i.e., tachycardia-bradycardia syndrome)
  - Ventricular arrhythmias including frequent premature ventricular contractions, ventricular tachycardia, and ventricular fibrillation
- **Sudden cardiac death** may occur with progressive disease. Although more malignant, life-threatening arrhythmias may occur with longstanding and usually previously symptomatic DCM, sudden cardiac

death can also be the presenting manifestation of *LMNA*-related DCM, with minimal or no left ventricular dysfunction [Meune et al 2006].

- **Variable DCM.** Only mild-to-moderate left ventricular dilatation despite progressive disease has been noted by some investigators. Therefore, *LMNA*-related DCM may be an appropriate diagnosis in those with an *LMNA* pathogenic variant who have clinical conduction system disease and/or arrhythmia prior to the left ventricular enlargement or with minimal or no systolic dysfunction.
- **Skeletal muscle disorder.** Occasionally, individuals with *LMNA*-related cardiomyopathy also manifest signs or symptoms of skeletal myopathy, which may be associated with elevated serum creatine kinase concentration.

Large prospective longitudinal studies to define the range of natural history of individuals with *LMNA* pathogenic variants have not yet been published.

## Genotype-Phenotype Correlations

No specific genotype-phenotype correlations have been established for *LMNA*-related DCM.

A few studies focusing on pathogenic variant type suggest a correlation between splice site variants and increased risk for sudden cardiac death [van Rijsingen et al 2012], and between non-missense variants (indel, truncating, splice site) and risk for malignant ventricular arrhythmias.

## Penetrance

*LMNA*-related DCM demonstrates age-related penetrance with onset in the third and fourth decades, so that by the seventh decade penetrance is considered greater than 90%-95%.

## Prevalence

Second to *TTN*, *LMNA* is the most common genetic cause of nonsyndromic DCM. Estimates of the frequency of *LMNA*-related DCM in persons with DCM of unknown cause (also referred to as idiopathic dilated cardiomyopathy) ranges from 5% to 13% [Morales et al 2020, Rosenbaum et al 2020].

## Genetically Related (Allelic) Disorders

Pathogenic variants in *LMNA* have been reported in individuals with a phenotype consistent with [arrhythmogenic right ventricular cardiomyopathy](#) – although after gene curation by ClinGen, the relationship with ARVC meeting the 2010 ARVC clinical Task Force Criteria was [limited](#) [James et al 2021].

Pathogenic variants have also been identified in several disorders of striated muscle, nerve, adipose, and vascular tissue, collectively referred to as the **laminopathies**. Laminopathies result primarily from pathogenic missense variants, with occasional nonsense and splice-site variants, as well as short insertions or deletions. A remarkable exception is the synonymous variant (a nucleotide change that does not alter the amino acid) in *LMNA* codon 608 (GGC changed to GGT that does not change the Gly608 residue) causing [Hutchinson-Gilford progeria](#).

Table 2 reviews selected *LMNA* allelic disorders; for other phenotypes associated with pathogenic variants in *LMNA*, see OMIM [150330](#).

**Table 2.** Selected *LMNA* Allelic Disorders

Disorder	MOI	Clinical Characteristics / Comment
<a href="#">Arrhythmogenic right ventricular cardiomyopathy</a> / Arrhythmogenic cardiomyopathy	AD	Progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia & sudden death. While initially described as primarily affecting the right ventricle, biventricular involvement has been observed w/ occasional presentations mimicking DCM.

Table 2. continued from previous page.

Disorder	MOI	Clinical Characteristics / Comment
<a href="#">Charcot-Marie-Tooth hereditary neuropathy type 2B1</a>	AR	Chronic motor & sensory polyneuropathy
<a href="#">Dunnigan-type familial partial lipodystrophy (FPLD2) (OMIM 151660)</a>	AD	Adipocytes degenerate during puberty, followed by abnormal fat deposition, glucose intolerance, & late-onset diabetes mellitus. Most FPLD2-causing <i>LMNA</i> pathogenic variants involve arginine at amino acid residue 482.
<a href="#">Emery-Dreifuss muscular dystrophy</a>	AD AR	Humero-peroneal muscular dystrophy (See also Differential Diagnosis.)
<a href="#">Heart-hand syndrome, Slovenian type (OMIM 610140)</a>	AD	DCM w/conduction system disease & variable degrees of brachydactyly
<a href="#">Hutchinson-Gilford progeria syndrome</a>	AD	Clinical features that typically develop in childhood & resemble some features of accelerated aging

AD = autosomal dominant; AR = autosomal recessive; DCM = dilated cardiomyopathy; MOI = mode of inheritance

## Differential Diagnosis

The genetic differential diagnosis of idiopathic dilated cardiomyopathy (DCM) should include all genes known to be associated with nonsyndromic DCM. Particular attention can be focused on nonsyndromic DCM-related genes that have been associated with arrhythmia and conduction system disease phenotypes (see [Dilated Cardiomyopathy Overview, Table 2. Nonsyndromic Dilated Cardiomyopathy Genes: Distinguishing Features](#)).

For individuals with a clinical diagnosis of idiopathic DCM and/or conduction disease/arrhythmias in whom molecular genetic testing fails to identify a pathogenic variant in *LMNA* or another gene associated with nonsyndromic DCM, physical examination to evaluate for extra-cardiac features (especially neuromuscular issues) or additional study of the cardiovascular findings may lead to a diagnosis of other disorders causing DCM and conduction system disease or other cardiomyopathies with or without neuromuscular disease that may resemble a DCM phenotype such as [arrhythmogenic right ventricular cardiomyopathy / arrhythmogenic cardiomyopathy](#), [DES-related myopathy \(OMIM 601419\)](#), [limb-girdle muscular dystrophy \(see OMIM Autosomal Dominant Limb-Girdle Muscular Dystrophy \[LGMD\] and Autosomal Recessive LGMD Phenotypic Series\)](#), and [Emery-Dreifuss Muscular Dystrophy](#).

## Management

[Guidelines](#) for the clinical evaluation and surveillance of individuals with *LMNA*-related DCM and other genetic cardiomyopathies have been published [Hershberger et al 2018]. Additional guidance regarding the management of arrhythmic disease in *LMNA*-related DCM is also available [Towbin et al 2019].

## Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with *LMNA*-related DCM, the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.



**Table 3.** Recommended Evaluations Following Initial Diagnosis in Individuals with *LMNA*-Related DCM

System/Concern	Evaluation	Comment
<b>Conduction system disease &amp; arrhythmia</b>	Comprehensive cardiovascular eval incl clinical cardiovascular history & physical exam. Review history of presyncope, syncope, resuscitated sudden cardiac death, palpitations, & other symptoms of conduction system disease & arrhythmia	
	EKG	Follow up of abnormalities w/addl testing as indicated; e.g., 24-hr monitoring or event monitors, exercise EKG, or invasive electrophysiologic eval for conduction system disease [Towbin et al 2019]
<b>Left ventricular dysfunction &amp; DCM</b>	Review history of shortness of breath, dyspnea on exertion, paroxysmal nocturnal dyspnea, chest pain.	
	Assessment of left ventricular enlargement & function by 2-dimensional echocardiography or cardiac MRI	Radionuclide ventriculography is an alternative measure of the ejection fraction.
<b>Skeletal myopathy</b>	<ul style="list-style-type: none"> <li>Assessment for skeletal muscle weakness</li> <li>Serum CK level</li> </ul>	If skeletal muscle weakness or ↑ CK, neuromuscular eval is indicated.
<b>Genetic counseling</b>	By genetics professionals <sup>1</sup>	To inform affected persons & their families re nature, MOI, & implications of <i>LMNA</i> -related DCM in order to facilitate medical & personal decision making

CK = creatine kinase; MOI = mode of inheritance

1. Medical geneticist, certified genetic counselor, certified advanced genetic nurse

## Treatment of Manifestations

Management guidelines for genetic cardiomyopathies have been published [Hershberger et al 2018, Towbin et al 2019]. Elements of the guidelines include the following:

- Because of the complexity of treatment interventions in *LMNA*-related DCM in symptomatic and asymptomatic individuals, referral to centers with special expertise in cardiovascular genetic medicine should be considered.
- Consider therapy based on cardiac phenotype (i.e., DCM or arrhythmia).
- With an established arrhythmia or known risk of arrhythmia, consider ICD implantation before the ejection fraction falls below 35%. Note that this recommendation was included in the Heart Failure Society guidelines in large part because of the risk for lethal arrhythmias in persons with an *LMNA* pathogenic variant who have systolic function well above a left ventricular ejection fraction of 35%, the usual measure of systolic dysfunction below which ICDs are indicated in most US guidelines.

The management of *LMNA*-related DCM is focused on treatment of **conduction system disease, arrhythmia, and DCM**.

**Table 4.** Treatment of Manifestations in Individuals with *LMNA*-related DCM

Manifestation/Concern	Treatment
<b>Cardiac conduction system disease &amp; arrhythmias</b>	For chronic atrial fibrillation unresponsive to cardioversion: <ul style="list-style-type: none"> <li>• Anticoagulants</li> <li>• Agents for ventricular rate control</li> </ul>

Table 4. continued from previous page.

Manifestation/Concern	Treatment
	<p>For other symptomatic supraventricular arrhythmias:</p> <ul style="list-style-type: none"> <li>• Pharmacologic agents</li> <li>• May be augmented with electrophysiologic intervention (e.g., atrial or atrioventricular node ablations)</li> </ul>
	<p>For symptomatic bradyarrhythmias or asymptomatic but significant heart block:</p> <ul style="list-style-type: none"> <li>• An implantable electronic pacemaker</li> <li>• Strongly consider an ICD (not an electronic pacemaker) due to risk of mortality from sudden cardiac death.</li> </ul>
	<p>For symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, &amp; resuscitated sudden cardiac death:</p> <ul style="list-style-type: none"> <li>• Use of an ICD</li> <li>• Drug therapy as needed</li> </ul>
<b>Dilated cardiomyopathy</b>	ACE inhibitors, beta blockers, diuretics, & other conventional approaches, as summarized in Yancy et al [2013] ( <a href="#">full text</a> )
	When DCM is present & left ventricular ejection fraction is <35% (w/or w/o arrhythmia): use of an ICD
	For progressive deterioration in left ventricular function despite full medical & device therapy, consider: <ul style="list-style-type: none"> <li>• Cardiac transplantation;</li> <li>• Durable mechanical circulatory support if cardiac transplantation is contraindicated.</li> </ul>

ICD = implantable cardioverter defibrillator

## Surveillance

Table 5. Recommended Surveillance for Individuals with *LMNA*-related DCM

System/Concern	Evaluation	Frequency
<b><i>LMNA</i> variant w/any EKG abnormality</b>	Cardiovascular eval for disease progression w/EKG, 24-48 hr rhythm monitoring, LV function measurement	Annually (at a minimum)
<b><i>LMNA</i> variant in an asymptomatic person</b>	Cardiovascular eval (medical history, physical exam, echocardiogram, & EKG)	Every 1-2 yrs &/or whenever new symptoms arise

## Agents/Circumstances to Avoid

Drugs (beta blockers, calcium channel blockers, others) that exacerbate heart block, if present, should be avoided in *LMNA*-related DCM unless an electronic pacemaker or implantable cardioverter defibrillator is in place.

## Evaluation of Relatives at Risk

Once a molecular diagnosis of *LMNA*-related DCM has been established in a family, molecular genetic testing for the familial *LMNA* pathogenic variant can be offered to relatives at risk in order to facilitate prompt diagnosis, surveillance, and treatment in those in whom the *LMNA* pathogenic variant has been detected.

The risk of DCM to family members who do not have the *LMNA* pathogenic variant identified in the proband is generally considered to be similar to that of the general population. However, because multiple variants in



DCM-associated genes have been observed in individuals with nonsyndromic DCM [Morales et al 2020] and because families may segregate pathogenic variants in more than one DCM-related gene [Liu et al 2015, Cowan et al 2018], thorough individualized risk assessment through clinical, genetic, and family history analysis is warranted to determine if discharge from high-risk cardiac surveillance is appropriate.

If molecular genetic testing is not possible, the first-degree relatives of a proband with *LMNA*-related DCM should be evaluated annually by medical history, physical examination, echocardiogram, and EKG to determine if any have detectable DCM and/or conduction system disease.

Note: Because the age of onset is variable and penetrance is reduced, a normal baseline echocardiogram and EKG in a first-degree relative who has not undergone molecular genetic testing does not rule out *LMNA*-related DCM in that individual, and the recommendations set forth in Surveillance should be followed.

Any abnormal cardiovascular test results in a relative of a proband with a known *LMNA* pathogenic variant should be followed up with a full cardiovascular assessment to evaluate for any acquired causes of disease (e.g., coronary artery disease). Results on screening tests that do not meet criteria for DCM but do show some abnormality (e.g., left ventricular enlargement but normal function; decreased ejection fraction but normal-sized left ventricle) may reflect variable expression of *LMNA*-related DCM in that relative. Targeted genetic testing to clarify the diagnosis as well as close surveillance (e.g., cardiovascular testing every 1-2 years) for progression of cardiovascular disease is recommended for such individuals.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Pregnancy Management

Pregnancy is contraindicated in women with DCM because of the significantly increased mortality with pregnancy in DCM. Women with DCM who become pregnant should be followed by a high-risk obstetrician. At-risk women with unknown genetic status should undergo a cardiovascular evaluation and be offered genetic counseling prior to pregnancy.

## Therapies Under Investigation

Drugs aimed at reducing mitogen-activated protein (MAP) kinase signaling, a mechanism which has been shown to be increased in *LMNA*-associated DCM, are actively under investigation (ClinicalTrials.gov identifier NCT02351856) [Wu et al 2011, MacRae et al 2016].

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

*LMNA*-related dilated cardiomyopathy (DCM) is inherited in an autosomal dominant manner.

## Risk to Family Members

### Parents of a proband

- Some individuals diagnosed with *LMNA*-related DCM have an affected parent.  
Note: Both sides of the family should be considered as possibly contributing. Families with DCM in both maternal and paternal lineages have been described [Liu et al 2015, Cowan et al 2018], and experience has shown that regardless of an apparent inheritance pattern in a family, assumptions regarding maternal or paternal inheritance of pathogenic variants in genes causing familial DCM in a given family may be unreliable and potentially misleading.
- Some individuals diagnosed with *LMNA*-related DCM have the disorder as the result of a *de novo* pathogenic variant. The proportion of individuals with *LMNA*-related DCM caused by a *de novo* pathogenic variant is unknown.
- Recommendations for the evaluation of reportedly unaffected parents of a proband include:
  - Review of medical history, physical examination, echocardiogram, and EKG to determine if a parent has detectable DCM and/or conduction system disease. Evaluation of parents may determine that one is affected but has previously escaped diagnosis possibly because of a milder phenotypic presentation (e.g., evidence of DCM on echocardiogram without clinical heart failure symptoms).
  - Molecular genetic testing for the familial *LMNA* pathogenic variant. Because *LMNA*-related DCM demonstrates age-related penetrance, an asymptomatic parent may be found to be heterozygous for the familial *LMNA* pathogenic.
- If the *LMNA* pathogenic variant identified in the proband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:
  - The proband has a *de novo* pathogenic variant.
  - The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.

**Sibs of a proband.** The risk to the sibs of the proband depends on the genetic status of the proband's parents:

- If one parent of the proband has the *LMNA* pathogenic variant, the risk to the sibs of inheriting the variant is 50%. However, because of variable expression and reduced penetrance, no predictions can be made regarding age of onset, severity, or course of disease in sibs who inherit the pathogenic variant.
- Due to reduced penetrance, variable expression, and potentially subtle or unknown early cardiovascular phenotypes in the progression of *LMNA*-associated cardiomyopathy, the apparent absence of symptoms in parents who have not undergone molecular genetic testing should not be used to modify risk to sibs. Sibs should be considered to be at up to a 50% risk of developing features of *LMNA*-associated cardiomyopathy unless molecular genetic testing has confirmed that neither parent is heterozygous for the *LMNA* pathogenic identified in the proband. Recommendations for evaluation of sibs are included in Evaluation of Relatives at Risk.
- If the *LMNA* pathogenic variant identified in the proband cannot be detected in the leukocyte DNA of either parent and parental identity testing has confirmed biological maternity and paternity, the recurrence risk to sibs is estimated to be 1% because of the theoretic possibility of parental germline mosaicism [Rahbari et al 2016].
- Sibs may be offered genetic testing for the familial *LMNA* pathogenic variant to help clarify risk. In general, sibs without the *LMNA* pathogenic variant identified in the proband are no longer considered to be at increased risk for DCM and thus may be discharged from cardiac surveillance. However, because multiple variants in DCM-associated genes have been observed in individuals with nonsyndromic DCM [Morales et al 2020] and because families may segregate pathogenic variants in more than one DCM-related gene [Liu et al 2015, Cowan et al 2018], thorough individualized risk assessment through clinical,

genetic, and family history analysis is warranted to determine if discharge from high-risk cardiac surveillance is appropriate.

**Offspring of a proband.** Each child of an individual with *LMNA*-related DCM has a 50% chance of inheriting the pathogenic variant identified in the proband. However, because of variable expression and reduced penetrance, no predictions can be made regarding age of onset, severity, or course of disease.

**Other family members.** The risk to other family members depends on the status of the proband's parents: if a parent has an *LMNA* pathogenic variant, his or her family members may be at risk regardless of the clinical status of the parent.

## Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

### Predictive testing (i.e., testing of asymptomatic at-risk individuals)

- Predictive testing for at-risk relatives is possible once the *LMNA*-related DCM pathogenic variant has been identified in an affected family member.
- Testing of asymptomatic at-risk individuals is considered predictive testing for predisposition to *LMNA*-related DCM, not diagnostic testing.
- Predictive testing should only be performed in the context of formal genetic counseling, and is not useful in predicting age of DCM onset, severity, or rate of progression.

### Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals age <18 years)

- Recent estimates of the likelihood of clinically detectable presentation of *LMNA*-related DCM in children is ~1.4% [Ware et al 2022]. Although relatively low, genetic testing should be offered as it can facilitate identification of at-risk children who may benefit from early treatment, potentially forestalling the development of advanced disease.
- In families with early-onset aggressive disease, identification of the familial pathogenic variant may guide more stringent clinical screening for asymptomatic but clinically detectable cardiovascular disease.
- See the American Academy of Pediatrics and American College of Medical Genetics and Genomics [policy statement](#) for discussion of ethical and policy issues in genetic testing and screening of children.

In a family with an established diagnosis of *LMNA*-related DCM, it is appropriate to consider testing of symptomatic individuals regardless of age.

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

## Prenatal Testing and Preimplantation Genetic Testing

Once an *LMNA* pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic testing are possible.

Differences in perspective exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

## Resources

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **American Heart Association**  
[Dilated Cardiomyopathy \(DCM\)](#)
- **Cardiomyopathy UK**  
United Kingdom  
**Phone:** 0800 018 1024 (UK only)  
**Email:** [contact@cardiomyopathy.org](mailto:contact@cardiomyopathy.org)  
[cardiomyopathy.org](http://cardiomyopathy.org)
- **Children's Cardiomyopathy Foundation**  
[www.childrenscardiomyopathy.org](http://www.childrenscardiomyopathy.org)
- **DCM Foundation**  
**Phone:** 833-DCM-HOPE (833-326-4673)  
**Email:** [Info@DCMFoundation.org](mailto:Info@DCMFoundation.org)  
[www.dcmfoundation.org](http://www.dcmfoundation.org)
- **Dilated Cardiomyopathy Research Project**  
**Phone:** 877-800-8430  
**Email:** [DCM.Research@osumc.edu](mailto:DCM.Research@osumc.edu)  
[www.dcmproject.com](http://www.dcmproject.com)
- **MedlinePlus**  
[Familial dilated cardiomyopathy](#)
- **Sudden Arrhythmia Death Syndromes (SADS) Foundation**  
**Phone:** 801-948-0654  
[www.sads.org](http://www.sads.org)

## Molecular Genetics

*Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.*

**Table A.** LMNA-Related Dilated Cardiomyopathy: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
<a href="#">LMNA</a>	<a href="#">1q22</a>	<a href="#">Prelamin-A/C</a>	<a href="#">LMNA homepage - Leiden Muscular Dystrophy pages</a>	<a href="#">LMNA</a>	<a href="#">LMNA</a>

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for LMNA-Related Dilated Cardiomyopathy (View All in OMIM)

115200	CARDIOMYOPATHY, DILATED, 1A; CMD1A
150330	LAMIN A/C; LMNA

## Molecular Pathogenesis

*LMNA* encodes two proteins: lamin A and lamin C. Both lamins A and C are structural proteins of the inner nuclear membrane and are found in many different tissues. While the role and function of lamin proteins are clearly essential to several mechanical processes, the mechanism of cellular injury that causes *LMNA*-related DCM remains incompletely understood. Because lamin A/C is a structural protein of the nuclear membrane, it has been suggested that fragility of the nuclear membrane in the setting of repetitive contraction of skeletal or cardiac muscle may predispose to nuclear injury and cellular apoptosis. An alternative hypothesis suggests that an abnormal lamin A/C protein may disrupt the chromatin/lamin-associated protein complex, thereby disturbing gene expression [Chen et al 2019].

**Mechanism of disease causation.** *LMNA*-related DCM has been shown to occur via a loss-of-function mechanism associated with indel, splicing, or missense variants [Chen et al 2019], and to include both truncating and non-truncating variants in *LMNA* [Mazzarotto et al 2020].

NOTE: Curation of clinical and experimental evidence through the ClinGen DCM Gene Curation efforts resulted in a definitive classification for the relationship of *LMNA* variants with the DCM phenotype (see [Gene-Disease Validity Classification Summary: LMNA - dilated cardiomyopathy](#)) [Jordan et al 2021].

## Chapter Notes

### Author Notes

Website: [Dilated Cardiomyopathy Research Project](#)

The Dilated Cardiomyopathy Research Project, originally launched in 1993 by Dr. Ray Hershberger while at the Oregon Health & Science University, aims to advance our understanding of dilated cardiomyopathy genetics. Multiple studies including data from more than 1500 families affected by DCM across the country have contributed genetic and clinical information to this research program. This multi-institutional effort, still led by Dr Hershberger and now housed at The Ohio State University, leverages the many sites collaborating in the DCM Consortium to identify families eligible for studies within the DCM Research Project, including the recently completed DCM Precision Medicine Study and the ongoing DCM Discovery Study. More information about the DCM Project, affiliated research studies, and other information and resources can be found on the website ([www.dcmproject.com](http://www.dcmproject.com)) or by emailing [dcm.research@osumc.edu](mailto:dcm.research@osumc.edu).

## Acknowledgments

We are deeply grateful for the numerous families who have contributed to the research efforts in the DCM Research Project over the past nearly three decades. Without their gracious participation and engagement, the advances driven by the work of the DCM Research Project to the field would not be possible.

## Author History

Jason Cowan, MS; University of Miami Miller School of Medicine (2008-2011)

Ray E Hershberger, MD (2008-present)

Ana Morales, MS, CGC; The Ohio State University (2008-2011; 2013-2021)

Elizabeth Jordan, MMSc, CGC (2022-present)

## Revision History

- 17 March 2022 (ha) Comprehensive update posted live
- 7 July 2016 (ha) Comprehensive update posted live
- 19 September 2013 (me) Comprehensive update posted live
- 5 April 2011 (me) Comprehensive update posted live
- 12 June 2008 (me) Review posted live
- 7 January 2008 (rh) Original submission

## References

### Published Guidelines/Consensus Statements

- Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available [online](#). 2013. Accessed 3-8-22.
- Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM, et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Available [online](#). 2018. Accessed 3-8-22.
- National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available [online](#). 2018. Accessed 3-8-22.
- Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chillou C, DePasquale EC, Desai MY, Estes NAM 3rd, Hua W, Indik JH, Ingles J, James CA, John RM, Judge DP, Keegan R, Krahn AD, Link MS, Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W, van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Available [online](#). 2019. Accessed 3-8-22.

### Literature Cited

- Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, Kirklín JK, Weintraub WS. 2021 ACC/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). *J Am Coll Cardiol*. 2021;77:2053–150. PubMed PMID: 33250265.
- Brodt C, Siegfried JD, Hofmeyer M, Martel J, Rampersaud E, Li D, Morales A, Hershberger RE. Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. *J Card Fail*. 2013;19:233–9. PubMed PMID: 23582089.
- Chen SN, Sbaizero O, Taylor MRG, Mestroni L. Lamin A/C Cardiomyopathy: Implications for Treatment. *Curr Cardiol Rep*. 2019;21:160. PubMed PMID: 31773301.
- Cirino AL, Cuddy S, Lakdawala NK. Deletion of entire LMNA gene as a cause of cardiomyopathy. *HeartRhythm Case Rep*. 2020;6:395–7. PubMed PMID: 32695585.
- Cowan JR, Kinnamon DD, Morales A, Salyer L, Nickerson DA, Hershberger RE. Multigenic Disease and Bilineal Inheritance in Dilated Cardiomyopathy Is Illustrated in Nonsegregating LMNA Pedigrees. *Circ Genom Precis Med*. 2018;11:e002038. PubMed PMID: 30012837.
- Gupta P, Bilinska ZT, Sylvius N, Boudreau E, Veinot JP, Labib S, Bolongo PM, Hamza A, Jackson T, Ploski R, Walski M, Grzybowski J, Walczak E, Religa G, Fidzianska A, Tesson F. Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin A/C gene is associated with cardiomyocyte nuclear envelope disruption. *Basic Res Cardiol*. 2010;105:365–77. PubMed PMID: 20127487.



- Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM, et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2018;20:899–909. PubMed PMID: 29904160.
- James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, Pilichou K, Domingo AM, Murray B, Cadrin-Tourigny J, Lekanne Deprez R, Celeghin R, Protonotarios A, Asatryan B, Brown E, Jordan E, McGlaughon J, Thaxton C, Kurtz CL, van Tintelen JP. International evidence-based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the Clinical Genome Resource Framework. *Circ Genom Precis Med*. 2021;14:e003273. PubMed PMID: 33831308.
- Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, Celeghin R, Edwards M, Fan J, Ingles J, James CA, Jarinova O, Johnson R, Judge DP, Lahrouchi N, Lekanne Deprez RH, Lumbers RT, Mazzarotto F, Medeiros Domingo A, Miller RL, Morales A, Murray B, Peters S, Pilichou K, Protonotarios A, Semsarian C, Shah P, Syrris P, Thaxton C, van Tintelen JP, Walsh R, Wang J, Ware J, Hershberger RE. Evidence-based assessment of genes in dilated cardiomyopathy. *Circulation*. 2021;144:7–19. PubMed PMID: 33947203.
- Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, Waintraub X, Charron P, Rollin A, Richard P, Stevenson WG, Macintyre CJ, Ho CY, Thompson T, Vohra JK, Kalman JM, Zeppenfeld K, Sacher F, Tedrow UB, Lakdawala NK. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. *J Am Coll Cardiol*. 2016;68:2299–307. PubMed PMID: 27884249.
- Liu GS, Morales A, Vafiadaki E, Lam CK, Cai WF, Haghighi K, Adly G, Hershberger RE, Kranias E. A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. *Cardiovasc Res*. 2015;107:164–74. PubMed PMID: 25852082.
- MacRae CA, Roden DM, Loscalzo J. The future of cardiovascular therapeutics. *Circulation*. 2016;133:2610–7. PubMed PMID: 27324356.
- Mazzarotto F, Tayal U, Buchan RJ, Midwinter W, Wilk A, Whiffin N, Govind R, Mazaika E, de Marvao A, Dawes TJW, Felkin LE, Ahmad M, Theotokis PI, Edwards E, Ing AY, Thomson KL, Chan LLH, Sim D, Baksi AJ, Pantazis A, Roberts AM, Watkins H, Funke B, O'Regan DP, Olivotto I, Barton PJR, Prasad SK, Cook SA, Ware JS, Walsh R. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. *Circulation*. 2020;141:387–98. PubMed PMID: 31983221.
- Meune C, van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. *N Engl J Med*. 2006;354:209–10. PubMed PMID: 16407522.
- Morales A, Kinnamon DD, Jordan E, Platt J, Vatta M, Dorschner MO, Starkey CA, Mead JO, Ai T, Burke W, Gastier-Foster J, Jarvik GP, Rehm HL, Nickerson DA, Hershberger RE, et al. Variant interpretation for dilated cardiomyopathy: refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. *Circ Genom Precis Med*. 2020;13:e002480. PubMed PMID: 32160020.
- Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al. Timing, rates and spectra of human germline mutation. *Nat Genet*. 2016;48:126–33. PubMed PMID: 26656846.
- Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical implications for heart failure management. *Nat Rev Cardiol*. 2020;17:286–97. PubMed PMID: 31605094.
- Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. *Hum Genet*. 2020;139:1197–207. PubMed PMID: 32596782.
- Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chillou C, DePasquale EC, Desai MY, Estes NAM 3rd, Hua W, Indik JH, Ingles J, James CA, John RM, Judge DP, Keegan R, Krahn AD, Link MS, Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W, van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk

stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*. 2019;16:e301–72. PubMed PMID: 31078652.

van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S, Rowland C, Aslam U, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH, Charron P, Pinto YM. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. *J Am Coll Cardiol*. 2012;59:493–500. PubMed PMID: 22281253.

van Tintelen JP, Tio RA, Kerstjens-Frederikse WS, van Berlo JH, Boven LG, Suurmeijer AJ, White SJ, den Dunnen JT, te Meerman GJ, Vos YJ, van der Hout AH, Osinga J, van den Berg MP, van Veldhuisen DJ, Buys CH, Hofstra RM, Pinto YM. Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene. *J Am Coll Cardiol*. 2007;49:2430–9. PubMed PMID: 17599607.

Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. *Circulation*. 1997;96:1863–73. PubMed PMID: 9323074.

Ware SM, Bhatnagar S, Dexheimer PJ, Wilkinson JD, Sridhar A, Fan X, Shen Y, Tariq M, Schubert JA, Colan SD, Shi L, Canter CE, Hsu DT, Bansal N, Webber SA, Everitt MD, Kantor PF, Rossano JW, Pahl E, Rusconi P, Lee TM, Towbin JA, Lal AK, Chung WK, Miller EM, Aronow B, Martin LJ, Lipshultz SE, et al. The genetic architecture of pediatric cardiomyopathy. *Am J Hum Genet*. 2022;109:282–98. PubMed PMID: 35026164.

Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. *Circulation*. 2011;123:53–61. PubMed PMID: 21173351.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62:e147–239. PubMed PMID: 23747642.

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).